SEC Form 4 · accession 0001209191-17-038901
ANTARES PHARMA, INC. · ATRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert F Apple
Officer — President & CEO · Director
Period of report
Feb 22, 2017
Accepted (ET)
Jun 9, 2017 · 4:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001016169
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 22, 2017 | A | 5,612 | $0.00 | A | 895,612 | D | |
| Common Stock | Feb 22, 2017 | F | 1,763 | $2.37 | D | 893,849 | D | |
| Common Stock | May 28, 2017 | F | 14,903 | $2.51 | D | 878,946 | D | |
| Common Stock | May 29, 2017 | F | 3,390 | $2.51 | D | 875,556 | D | |
| Common Stock | Jun 2, 2017 | F | 38,034 | $2.57 | D | 837,522 | D | |
| Common StockF5 | Jun 7, 2017 | A | 338,115 | $2.66 | D | 1,175,637 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F6,F7 | $2.66 | Jun 7, 2017 | A | 725,751 | A | — | Jun 7, 2027 | Common Stock | 725,751 | 725,751 | D |
Explanation of responses
- F1On May 22, 2013, Mr. Apple was granted a performance stock unit award that was contingent upon the Company achieving certain performance goals over a three year performance period ended December 31, 2016. The shares reported here represent the total number of shares that were earned upon the achievement and certification of one of the performance goals, which was net settled. The shares disposed represents the shares withheld to settle tax liability in connection with the vesting of the performance stock unit award.
- F2Represents shares withheld to settle tax liability in connection with the vesting of a restricted stock unit award that was previously granted on May 28, 2015.
- F3Represents shares withheld to settle tax liability in connection with the vesting of a restricted stock unit award that was previously granted on May 29, 2014.
- F4Represents shares withheld to settle tax liability in connection with the vesting of a restricted stock unit award that was previously granted on June 2, 2016.
- F5Represents grant of restricted stock units made under the Antares Pharma, Inc. 2008 Equity Compensation Plan. The shares vest in three equal annual installments from the date of grant.
- F6Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan.
- F7The options vest in equal quarterly installments over three years from the date of grant.